American Society of Retina Specialists Meeting
VIDEO: COVID-19 pandemic leads to ingenuity in ophthalmology treatment
In this video from the virtual American Society of Retina Specialists meeting,
More frequent anti-VEGF injections in AMD linked to increased cognitive impairment risk
Researchers linked higher frequency of intravitreal anti-VEGF injections with a greater risk for mild cognitive impairment in patients with age-related macular degeneration.
VIDEO: Software upgrade brings new customizations to 3D visualization
In this video from the virtual American Society of Retina Specialists meeting,
Metabolomics may enable early diagnosis, treatment in macular degeneration
Investigators reported that patients with age-related macular degeneration have a distinct plasma metabolomic profile compared with controls, according to research presented at the American Society of Retina Specialists annual meeting.
Nearly 1 in 5 wet AMD patients lost to follow-up after anti-VEGF injections
Study results showed a high rate of loss to follow-up in patients with neovascular age-related macular degeneration treated with anti-VEGF injections in the U.S., with nearly 1 in 5 patients lost to follow-up.
No single anti-VEGF regimen linked to superior vision outcomes in wet AMD
Different anti-VEGF regimens may not result in superior vision benefits compared with ranibizumab for neovascular age-related macular degeneration, according to a meta-analysis presented at the virtual American Society of Retina Specialists meeting.
Physician outcome measures do not accurately gauge ophthalmologists’ quality
Researchers found current Merit-based Incentive Payment System and future public reporting of physician scores for outcome measures used flawed methodology, questioning its ability to differentiate between high- and low-performing ophthalmologists.
Same-day exams during wet AMD anti-VEGF therapy could save up to $7 billion
The Modifier-25 same-day exams during anti-VEGF therapy for neovascular age-related macular degeneration reduced treatment and travel costs at the patient and population levels, according to an expert at the virtual American Society of Retina Specialists meeting.
Abicipar maintains vision gain in wet AMD with less frequent dosing
Visual gains attained in year 1 of the CEDAR and SEQUOIA trials sustained effectively with four injections of abicipar as with 12 injections of ranibizumab in year 2, according to data from the virtual American Society of Retina Specialists meeting.
Fluocinolone acetonide implant increases resolution of macular edema through 36 months
Patients with noninfectious uveitis affecting the posterior segment who were treated with a fluocinolone acetonide intravitreal implant experienced beneficial effects on macular edema through 36 months.